We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Affibody AB and GE Healthcare in Molecular Collaboration

By MedImaging staff writers
Posted on 28 Jun 2006
Print article
Affibody AB (Stockholm, Sweden) has entered a research agreement with GE Healthcare (Chalfont Sr. Giles, UK), a division of the General Electric Co.. Under the agreement, Affibody will provide Affibody molecules for three disease targets as defined by GE Healthcare.

Affibody molecules, with their favorable biodistribution, high target specificity, and acceptability to protein-engineering approaches, are considered suitable candidates for targeted in vivo imaging applications. The goal is to allow early diagnosis of disease and thereby allowing clinicians to optimize the therapy on a customized basis. Under the agreement, GE Healthcare has the exclusive option to take any licenses required for developing and marketing imaging agents resulting from this collaboration. Affibody retains all rights for use of the selected Affibody molecules outside the scope of in vivo diagnostic and medical imaging.

Dr. Ulf Boberg, chief executive officer, Affibody, commented, "We are delighted to announce an agreement with GE Healthcare, regarded as a leader in the rapidly expanding field of molecular imaging. This agreement broadens the current uses of Affibody molecules in medicine, and demonstrates the increasing interest in the use of molecular imaging agents to monitor disease.”

Affibody uses innovative protein engineering technologies for the development of the affinity ligand, Affibody molecules. These small, robust protein molecules can be designed to bind to a number of target proteins, are easily produced, and have a high stability in a broad range of conditions. They appear well-suited for molecular imaging, and when combined with a cytotoxic payload, could potentially be utilized for targeted therapy.

Affibody also develops Affibody molecules for various biotechnology applications in a number of commercial collaborations. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute (Stockholm, Sweden).



Related Links:
Affibody
GE Healthcare
3T MRI Scanner
MAGNETOM Cima.X
Radiology Software
DxWorks
New
Pocket Fetal Doppler
CONTEC10C/CL
Multi-Use Ultrasound Table
Clinton

Print article

Channels

Radiography

view channel
Image: The new machine algorithm can identify cardiovascular risk at the click of a button (Photo courtesy of Adobe Stock)

Machine Learning Algorithm Identifies Cardiovascular Risk from Routine Bone Density Scans

A new study published in the Journal of Bone and Mineral Research reveals that an automated machine learning program can predict the risk of cardiovascular events and falls or fractures by analyzing bone... Read more

MRI

view channel
Image: In brains of control mice (left) and PD mice (right), from bottom to top: neuronal activity in a representative animal (Photo courtesy of Ruxanda Lungu/FC)

Simple Brain Scan Diagnoses Parkinson's Disease Years Before It Becomes Untreatable

Parkinson's disease (PD) remains a challenging condition to treat, with no known cure. Though therapies have improved over time, and ongoing research focuses on methods to slow or alter the disease’s progression,... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more